Cargando…

Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study

Objective: This study aims to compare the treatment outcomes of concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in stage II nasopharyngeal carcinoma (NPC) patients. Methods: We retrospectively collected 601 stage II NPC patients treated in two hospitals between June 2003 to June 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Pei-Jing, Lai, Yu-Lin, He, Fang, Chen, Yuan-Yuan, Gu, Zhuo-Sheng, Luo, Wei, Zhang, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490628/
https://www.ncbi.nlm.nih.gov/pubmed/34621166
http://dx.doi.org/10.3389/fphar.2021.688528
_version_ 1784578553648513024
author Li, Pei-Jing
Lai, Yu-Lin
He, Fang
Chen, Yuan-Yuan
Gu, Zhuo-Sheng
Luo, Wei
Zhang, Qun
author_facet Li, Pei-Jing
Lai, Yu-Lin
He, Fang
Chen, Yuan-Yuan
Gu, Zhuo-Sheng
Luo, Wei
Zhang, Qun
author_sort Li, Pei-Jing
collection PubMed
description Objective: This study aims to compare the treatment outcomes of concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in stage II nasopharyngeal carcinoma (NPC) patients. Methods: We retrospectively collected 601 stage II NPC patients treated in two hospitals between June 2003 to June 2016. All patients were divided into the CCRT group (n = 255) and the RT group (n = 346). Overall survival (OS), locoregional failure-free survival (LRFFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) were assessed using the Kaplan-Meier method. The log-rank test was used to compare the differences between the groups. The Cox-regression hazards model was performed to determine potential prognostic factors. Results: The median follow-up was 99 months. No significant difference was found in locoregional recurrence, distant metastasis, disease progression, and death between the two groups (all p > 0.05). In univariate analysis, the 5-years OS, PFS, LRFFS, and DMFS had no significant differences between the CCRT and RT groups (all p > 0.05). Two-dimensional radiotherapy (2DRT) sub-analysis showed that CCRT remarkably increased DMFS, PFS, and OS rates (all p < 0.05) but not LRFFS (p = 0.258) compared with RT alone. While intensity-modulated radiotherapy (IMRT) sub-analysis showed that the prognosis of the two groups had no significant differences (all p > 0.05). In multivariate analyses, age was significantly and inversely related to OS, PFS, LRFFS, and DMFS. IMRT was an independent favorable factor for improving LRFFS, PFS, and OS. Concurrent chemotherapy was an independent protective factor for DMFS. Conclusion: In the context of 2DRT, it is definite that concurrent chemotherapy provides survival benefits for patients with stage II NPC. While in the IMRT era, the impact of chemotherapy on survival in patients with stage II NPC is weakened. Prospective randomized controlled studies are required to confirm these results.
format Online
Article
Text
id pubmed-8490628
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-84906282021-10-06 Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study Li, Pei-Jing Lai, Yu-Lin He, Fang Chen, Yuan-Yuan Gu, Zhuo-Sheng Luo, Wei Zhang, Qun Front Pharmacol Pharmacology Objective: This study aims to compare the treatment outcomes of concurrent chemoradiotherapy (CCRT) versus radiotherapy (RT) alone in stage II nasopharyngeal carcinoma (NPC) patients. Methods: We retrospectively collected 601 stage II NPC patients treated in two hospitals between June 2003 to June 2016. All patients were divided into the CCRT group (n = 255) and the RT group (n = 346). Overall survival (OS), locoregional failure-free survival (LRFFS), progression-free survival (PFS), and distant metastasis-free survival (DMFS) were assessed using the Kaplan-Meier method. The log-rank test was used to compare the differences between the groups. The Cox-regression hazards model was performed to determine potential prognostic factors. Results: The median follow-up was 99 months. No significant difference was found in locoregional recurrence, distant metastasis, disease progression, and death between the two groups (all p > 0.05). In univariate analysis, the 5-years OS, PFS, LRFFS, and DMFS had no significant differences between the CCRT and RT groups (all p > 0.05). Two-dimensional radiotherapy (2DRT) sub-analysis showed that CCRT remarkably increased DMFS, PFS, and OS rates (all p < 0.05) but not LRFFS (p = 0.258) compared with RT alone. While intensity-modulated radiotherapy (IMRT) sub-analysis showed that the prognosis of the two groups had no significant differences (all p > 0.05). In multivariate analyses, age was significantly and inversely related to OS, PFS, LRFFS, and DMFS. IMRT was an independent favorable factor for improving LRFFS, PFS, and OS. Concurrent chemotherapy was an independent protective factor for DMFS. Conclusion: In the context of 2DRT, it is definite that concurrent chemotherapy provides survival benefits for patients with stage II NPC. While in the IMRT era, the impact of chemotherapy on survival in patients with stage II NPC is weakened. Prospective randomized controlled studies are required to confirm these results. Frontiers Media S.A. 2021-09-21 /pmc/articles/PMC8490628/ /pubmed/34621166 http://dx.doi.org/10.3389/fphar.2021.688528 Text en Copyright © 2021 Li, Lai, He, Chen, Gu, Luo and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Li, Pei-Jing
Lai, Yu-Lin
He, Fang
Chen, Yuan-Yuan
Gu, Zhuo-Sheng
Luo, Wei
Zhang, Qun
Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
title Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
title_full Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
title_fullStr Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
title_full_unstemmed Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
title_short Explore the Usefulness of Concurrent Chemotherapy in Stage II Nasopharyngeal Carcinoma: A Retrospective Study
title_sort explore the usefulness of concurrent chemotherapy in stage ii nasopharyngeal carcinoma: a retrospective study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8490628/
https://www.ncbi.nlm.nih.gov/pubmed/34621166
http://dx.doi.org/10.3389/fphar.2021.688528
work_keys_str_mv AT lipeijing exploretheusefulnessofconcurrentchemotherapyinstageiinasopharyngealcarcinomaaretrospectivestudy
AT laiyulin exploretheusefulnessofconcurrentchemotherapyinstageiinasopharyngealcarcinomaaretrospectivestudy
AT hefang exploretheusefulnessofconcurrentchemotherapyinstageiinasopharyngealcarcinomaaretrospectivestudy
AT chenyuanyuan exploretheusefulnessofconcurrentchemotherapyinstageiinasopharyngealcarcinomaaretrospectivestudy
AT guzhuosheng exploretheusefulnessofconcurrentchemotherapyinstageiinasopharyngealcarcinomaaretrospectivestudy
AT luowei exploretheusefulnessofconcurrentchemotherapyinstageiinasopharyngealcarcinomaaretrospectivestudy
AT zhangqun exploretheusefulnessofconcurrentchemotherapyinstageiinasopharyngealcarcinomaaretrospectivestudy